EN | RU
EN | RU

Help Support

Back

Step-down therapy is not non-inferior to maintenance of treatment in asthma patients

Step-down therapy is not non-inferior to maintenance of treatment in asthma patients Step-down therapy is not non-inferior to maintenance of treatment in asthma patients
Step-down therapy is not non-inferior to maintenance of treatment in asthma patients Step-down therapy is not non-inferior to maintenance of treatment in asthma patients

What's new?

In asthma patients, stepping-down asthma controller treatment was not noninferior to the maintenance of therapy.

Stepping-down asthma controller therapy displayed noninferiority to the maintenance of therapy in patients with asthma who had been stable with low-dose inhaled corticosteroid/long-acting β2-agonist (ICS/LABA) for at least three months, concluded a trial published in "The Journal of Allergy and Clinical Immunology". Investigators compared the two kinds of step-down approaches for the maintenance of treatment.

This three-arm parallel, open-label, pragmatic randomized controlled trial enrolled a total of 225 participants (age 18 years or older) that were randomly divided into three groups:

  • Group 1 (G1): Maintenance on low-dose ICS/LABA
  • Group 2 (G2): Discontinued LABA
  • Group 3 (G3): Reduced ICS/LABA to once daily and were followed for six months.

The primary outcome was an alteration in asthma control test scores between randomization and the final six-month follow-up. In the per-protocol population, alteration in the asthma control test was analyzed.  As compared with the maintenance group, the non-inferiority was not illustrated in either of the step-down group. In the step-down groups, a greater rate of therapeutic failure was noted (although about 90% of patients were fine).


No vital differences between the step-down approaches were witnessed in terms of asthma control test change or therapeutic failure. The step-down strategy may be undertaken when the asthma patients are stable. However, adequate monitoring and supervision are crucial with precautions regarding the loss of disease control, concluded the authors. 

Source:

The Journal of Allergy and Clinical Immunology

Article:

Pragmatic Randomized Controlled Trial for Stepping Down Asthma Controller Treatment in Patients Controlled with Low-Dose Inhaled Corticosteroid and Long-Acting β2-Agonist: Step-Down of Intervention and Grade in Moderate Asthma Study

Authors:

Sae-Hoon Kim et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru ua
Try: